Search

Displaying results 1841 - 1850 of 8170 in total
  1. Drug

    Relutrigine

    go.drugbank.com/drugs/DB21614
    Investigational

    Relutrigine has a monoisotopic molecular weight of 407.08 Da. … Relutrigine is under investigation in clinical trial NCT07010471 (A Clinical Trial for Participants With DEE to Assess Efficacy, Safety, Tolerability, and PK of Relutrigine).

  2. Drug

    rdESAT-6

    go.drugbank.com/drugs/DB21906
    Approved

    rdESAT-6 is a recombinant dimer of _Mycobacterium tuberculosis_ early secretory antigenic target used as an ingredient in the diagnostic agent SIILTIBCY along with [rCFP-10].[L53638]

  3. Drug

    Testosterone propionate

    go.drugbank.com/drugs/DB01420
    ApprovedInvestigationalVet approvedWithdrawn

    Currently, this drug has been discontinued in humans, but the vet application is still available as an OTC.[L1160]

    Categories: Cytochrome P-450 Substrates, P-glycoprotein substrates
  4. Drug

    Talquetamab

    go.drugbank.com/drugs/DB16678
    ApprovedInvestigational

    Talquetamab is a IgG4-PAA bispecific G protein-coupled receptor class C group 5 member D (GPRC5D)-directed CD3 T-cell engager.

    Synonyms: ANTIBODY; BISPECIFIC GAMMA4 HEAVY CHAIN HUMANIZED AN, IMMUNOGLOBULIN G4-KAPPA/G4-LAMBDA, ANTI-(HOMO SAPIENS GPRC5D (G PROTEIN-COUPLED RECEPTOR CLASS C GROUP 5 MEMBER D)), AND ANTI-(HOMO SAPIENS CD3E (CD3 EPSILON, LEU-4)), HUMANIZED AND CHIMERIC MONOCLONAL
  5. Drug

    Xanomeline

    go.drugbank.com/drugs/DB15357
    ApprovedInvestigational

    Schizophrenia is a complex disease involving a number of different neurotransmitters, including serotonin, dopamine, and acetylcholine. Positive symptoms (e.g. hallucinations, delusions) have traditionally been attributed to increased do...

    Categories: P-glycoprotein inhibitors, Cytochrome P-450 Substrates
  6. Drug

    Flotufolastat F-18

    go.drugbank.com/drugs/DB17851
    ApprovedInvestigational

    [Flotufolastat] F-18 (<sup>18</sup>F-rhPSMA-7.3) is an <sup>18</sup>F-labeled ligand that targets the prostate-specific membrane antigen (PSMA). … Unlike <sup>68</sup>Ga-labeled PSMA-targeting ligands, <sup>18</sup>F-labeled compounds targeting this protein have a longer half-life and can be produced in larger batches.

  7. Drug

    Vorasidenib

    go.drugbank.com/drugs/DB17097
    ApprovedInvestigational

    [A264209] It works by suppressing the levels of D-2-hydroxyglutarate (2-HG), an oncometabolite produced by mutant IDH1 and IDH2 isoforms.

    Categories: Cytochrome P-450 CYP2B6 Inducers, Cytochrome P-450 Substrates
  8. Drug

    PF-04991532

    go.drugbank.com/drugs/DB11765
    Investigational

    PF-04991532 has been used in trials studying the basic science of Diabetes Mellitus, Type 2 Diabetes Mellitus, Diabetes Mellitus, Type 2, and Glucose Metabolism Disorders.

  9. Drug

    PL-3994

    go.drugbank.com/drugs/DB15355
    Investigational

    PL-3994 is under investigation in clinical trial NCT01304628 (Cross-Over Study of Subcutaneous Study Drug for the Treatment of Patients With Mild to Moderate Asthma).

  10. Drug

    Zolazepam

    go.drugbank.com/drugs/DB11555
    ExperimentalVet approved

    Zolazepam is a pyrazolodiazepinone derivative used as an anaesthetic in veterinary medicine. … It is around four times the potency of diazepam but it is both water-soluble and un-ionized at physiological pH meaning that its onset is very fast.